Recent progress in multidrug delivery to cancer cells by liposomes

Nanomedicine

Volumn 9, Issue 8, 2014, Pages 1117-1120

  Mo, Ran ^a,b,c   Jiang, Tianyue ^a,b,c   Gu, Zhen ^a,b  

^a USA and North Carolina State University   (United States)

^b University of North Carolina   (United States)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

chemotherapy; co delivery; combination cancer therapy; drug delivery; gene therapy; liposome; protein therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; ARGINYLGLYCYLASPARTIC ACID; CISPLATIN; CPX 1; CPX 351; DOXORUBICIN; FLUOXETINE; IRINOTECAN; LIPOSOME; MICRORNA; MYC PROTEIN; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NANOPARTICLE; PROTEIN MDM2; QUERCETIN; SMALL INTERFERING RNA; SUNITINIB; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VINCRISTINE SULFATE; VORINOSTAT;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GENE THERAPY; HUMAN; MACROMOLECULE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR REGRESSION; CHEMISTRY; NEOPLASMS;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; GENETIC THERAPY; HUMANS; LIPOSOMES; NEOPLASMS;

EID: 84906254352     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.62     Document Type: Review

References (24)

1. Bangham AD, Standish MM, Watkins JC et al. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 13(1), 238-252 (1965).
2. Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumor targeting. Nanomedicine 8(9), 1509-1528 (2013).
3. Wang B, Galliford CV, Low PS. Guiding principles in the design of ligand-targeted nanomedicines. Nanomedicine 9(2), 313-330 (2014).
4. Mayer LD, Harasym TO, Tardi PG et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol. Cancer Ther. 5 (7), 1854-1863 (2006).
5. Batist G, Gelmon KA, Chi KN et al. Safety, pharmacokinetics, and effcacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin. Cancer Res. 15(2), 692-700 (2009).
6. Feldman EJ, Lancet JE, Kolitz JE et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fxed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J. Clin. Oncol. 29(8), 979-985 (2011).
7. Feldman EJ, Kolitz JE, Trang JM et al. Pharmacokinetics of CPX-351; a nano-scale liposomal fxed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk. Res. 36(10), 1283-1289 (2012).
8. Wong MY, Chiu GN. Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model. Nanomedicine 7(6), 834-840 (2011).
9. Zucker D, Andriyanov AV, Steiner A et al. Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic effcacy. J. Controlled Release 160(2), 281-289 (2012).
10. Ong JC, Sun F, Chan E. Development of stealth liposome coencapsulating doxorubicin and fuoxetine. J. Liposome Res. 21(4), 261-271 (2011).
11. Sawant RR, Vaze OS, Rockwell K, Torchilin VP.Palmitoyl ascorbate-modifed liposomes as nanoparticle platform for ascorbate-mediated cytotoxicity and paclitaxel co-delivery. Eur. J. Pharm. Biopharm. 75(3), 321-326 (2010).
12. Maitani Y, Saito H, Seishi Y et al. A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse. J. Drug Target. 20(10), 873-882 (2012).
13. Zhang YF, Wang JC, Bian DY et al. Targeted delivery of RGD-modifed liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur. J. Pharm. Biopharm. 74(3), 467-473 (2010).
14. Chen Y, Zhu X, Zhang X, Liu B, Huang L. Nanoparticles modifed with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther. 18(9), 1650-1656 (2010).
15. Shim G, Han SE, Yu YH et al. Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug. J. Controlled Release 155(1), 60-66 (2011).
16. Kang SH, Cho HJ, Shim G et al. Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer effcacy. Pharm. Res. 28(12), 3069-3078 (2011).
17. Xiao W, Chen X, Yang L et al. Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome. Int. J. Pharm. 393(1-2), 119-126 (2010).
18. Zhang Y, Schwerbrock NMJ, Rogers AB et al. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol. Ther. 21(8), 1559-1569 (2013).
19. Zhang M, Garbuzenko OB, Reuhl KR, Rodriguez-Rodriguez L, Minko T., Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases. Nanomedicine 7(2), 185-197 (2012).
20. Sochanik A, Mitrus I, Smolarczyk R et al. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent. Arch. Immunol. Ther. Exp. (Warsz) 58(3), 235-245 (2010).
21. Koo YT, Falcao C, Torchilin VP. Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy. Mol. Pharm. 6(3), 971-977 (2009).
22. Jiang T, Mo R, Bellotti A et al. Gel-liposome-mediated co-delivery of anticancer membrane-associated proteins and small-molecule drugs for enhanced therapeutic effcacy. Adv. Funct. Mater.24(16), 2295-2304 (2014).
23. Wu GH, Milkhailovsky A, Khant HA et al. Remotely triggered liposome release by near-infrared light absorption via hollow gold nanoshells. J. Am. Chem. Soc. 130(26), 8175-8177 (2008).
24. Mo R, Jiang T, Gu Z. Enhanced anticancer effcacy by ATP-mediated liposomal. drug delivery. Angew. Chem. Int. Ed. 53(23), 5815-5820 (2014).